Localization of Damage in Progressive Hydroxychloroquine Retinopathy On and Off the Drug: Inner Versus Outer Retina, Parafovea Versus Peripheral Fovea

To evaluate the relative involvement of inner and outer retina in hydroxychloroquine (HCQ) retinopathy while on the drug, and after drug cessation, using data from spectral-domain optical coherence tomography (SD-OCT). A total of 102 SD-OCT scans were obtained from 11 patients (classified as having...

Full description

Saved in:
Bibliographic Details
Published inInvestigative ophthalmology & visual science Vol. 56; no. 5; pp. 3415 - 3426
Main Authors de Sisternes, Luis, Hu, Julia, Rubin, Daniel L., Marmor, Michael F.
Format Journal Article
LanguageEnglish
Published United States The Association for Research in Vision and Ophthalmology 01.05.2015
Subjects
Online AccessGet full text

Cover

Loading…
Abstract To evaluate the relative involvement of inner and outer retina in hydroxychloroquine (HCQ) retinopathy while on the drug, and after drug cessation, using data from spectral-domain optical coherence tomography (SD-OCT). A total of 102 SD-OCT scans were obtained from 11 patients (classified as having early, moderate, or severe stages of toxicity) over a period of 4 years after cessation of HCQ. The inner and outer retina boundaries were identified automatically to measure thickness and characterize progression topographically. The segmentation of retinal layers was verified in SD-OCT cross-sections for all eyes and scans included in this study (a total of 102 scans). Topographic analysis showed that inner retina was not involved in HCQ toxicity to any meaningful degree, either between stages of retinopathy or after the drug is stopped. The characteristic bull's eye pattern of outer macula thinning appears when comparing moderate retinopathy (before any RPE damage) to the early stage. Later damage, as toxicity evolved to a severe stage, was diffuse across most of the macula. If the drug was stopped at an early or moderate stage, progression was limited to the first year and occurred diffusely without parafoveal localization. Hydroxychloroquine retinopathy primarily involves outer retina (photoreceptors). Outer retinal thinning while using HCQ initially involves the parafovea, but becomes diffuse across the macula as damage progresses or after drug cessation. When HCQ is stopped at an early or moderate stage (before RPE damage), progression seems to be limited to the first year.
AbstractList To evaluate the relative involvement of inner and outer retina in hydroxychloroquine (HCQ) retinopathy while on the drug, and after drug cessation, using data from spectral-domain optical coherence tomography (SD-OCT). A total of 102 SD-OCT scans were obtained from 11 patients (classified as having early, moderate, or severe stages of toxicity) over a period of 4 years after cessation of HCQ. The inner and outer retina boundaries were identified automatically to measure thickness and characterize progression topographically. The segmentation of retinal layers was verified in SD-OCT cross-sections for all eyes and scans included in this study (a total of 102 scans). Topographic analysis showed that inner retina was not involved in HCQ toxicity to any meaningful degree, either between stages of retinopathy or after the drug is stopped. The characteristic bull's eye pattern of outer macula thinning appears when comparing moderate retinopathy (before any RPE damage) to the early stage. Later damage, as toxicity evolved to a severe stage, was diffuse across most of the macula. If the drug was stopped at an early or moderate stage, progression was limited to the first year and occurred diffusely without parafoveal localization. Hydroxychloroquine retinopathy primarily involves outer retina (photoreceptors). Outer retinal thinning while using HCQ initially involves the parafovea, but becomes diffuse across the macula as damage progresses or after drug cessation. When HCQ is stopped at an early or moderate stage (before RPE damage), progression seems to be limited to the first year.
To evaluate the relative involvement of inner and outer retina in hydroxychloroquine (HCQ) retinopathy while on the drug, and after drug cessation, using data from spectral-domain optical coherence tomography (SD-OCT).PURPOSETo evaluate the relative involvement of inner and outer retina in hydroxychloroquine (HCQ) retinopathy while on the drug, and after drug cessation, using data from spectral-domain optical coherence tomography (SD-OCT).A total of 102 SD-OCT scans were obtained from 11 patients (classified as having early, moderate, or severe stages of toxicity) over a period of 4 years after cessation of HCQ. The inner and outer retina boundaries were identified automatically to measure thickness and characterize progression topographically.METHODSA total of 102 SD-OCT scans were obtained from 11 patients (classified as having early, moderate, or severe stages of toxicity) over a period of 4 years after cessation of HCQ. The inner and outer retina boundaries were identified automatically to measure thickness and characterize progression topographically.The segmentation of retinal layers was verified in SD-OCT cross-sections for all eyes and scans included in this study (a total of 102 scans). Topographic analysis showed that inner retina was not involved in HCQ toxicity to any meaningful degree, either between stages of retinopathy or after the drug is stopped. The characteristic bull's eye pattern of outer macula thinning appears when comparing moderate retinopathy (before any RPE damage) to the early stage. Later damage, as toxicity evolved to a severe stage, was diffuse across most of the macula. If the drug was stopped at an early or moderate stage, progression was limited to the first year and occurred diffusely without parafoveal localization.RESULTSThe segmentation of retinal layers was verified in SD-OCT cross-sections for all eyes and scans included in this study (a total of 102 scans). Topographic analysis showed that inner retina was not involved in HCQ toxicity to any meaningful degree, either between stages of retinopathy or after the drug is stopped. The characteristic bull's eye pattern of outer macula thinning appears when comparing moderate retinopathy (before any RPE damage) to the early stage. Later damage, as toxicity evolved to a severe stage, was diffuse across most of the macula. If the drug was stopped at an early or moderate stage, progression was limited to the first year and occurred diffusely without parafoveal localization.Hydroxychloroquine retinopathy primarily involves outer retina (photoreceptors). Outer retinal thinning while using HCQ initially involves the parafovea, but becomes diffuse across the macula as damage progresses or after drug cessation. When HCQ is stopped at an early or moderate stage (before RPE damage), progression seems to be limited to the first year.CONCLUSIONSHydroxychloroquine retinopathy primarily involves outer retina (photoreceptors). Outer retinal thinning while using HCQ initially involves the parafovea, but becomes diffuse across the macula as damage progresses or after drug cessation. When HCQ is stopped at an early or moderate stage (before RPE damage), progression seems to be limited to the first year.
This report examines the involvement of inner and outer retina in hydroxychloroquine (HCQ) retinopathy, using automated pixel-by-pixel segmentation to measure thickness and rate of change in SD-OCT images. It extends understanding of how toxicity develops and progresses on and off the drug, and shows that HCQ retinopathy involves primarily the outer retina.
Author de Sisternes, Luis
Rubin, Daniel L.
Marmor, Michael F.
Hu, Julia
Author_xml – sequence: 1
  givenname: Luis
  surname: de Sisternes
  fullname: de Sisternes, Luis
  organization: Department of Radiology Stanford University, Stanford, California, United States
– sequence: 2
  givenname: Julia
  surname: Hu
  fullname: Hu, Julia
  organization: Department of Ophthalmology, Byers Eye Institute at Stanford, Stanford University School of Medicine, Palo Alto, California, United States
– sequence: 3
  givenname: Daniel L.
  surname: Rubin
  fullname: Rubin, Daniel L.
  organization: Department of Radiology Stanford University, Stanford, California, United States 3Department of Medicine (Biomedical Informatics), Stanford University, Stanford, California, United States
– sequence: 4
  givenname: Michael F.
  surname: Marmor
  fullname: Marmor, Michael F.
  organization: Department of Ophthalmology, Byers Eye Institute at Stanford, Stanford University School of Medicine, Palo Alto, California, United States
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26024126$$D View this record in MEDLINE/PubMed
BookMark eNptkctuEzEUhi1URC-wZIu8ZNEpvs5kWCBVLaWVIiWqgK3l8RxnjCZ2sD1Rw4P0eTtJG1RQV76c_2L5O0YHPnhA6D0lZ5SW1ScX1umMioKWXMhX6IhKyQpZTfjBs_0hOk7pFyGMUkbeoENWEiYoK4_Q_TQY3bs_OrvgcbD4Ui_1ArDzeB7DIkJKbg34etPGcLcxXR9i-D04D_gWsvNhpXO3wTOPtW_xzFqcO8CXcVh8xjfeQ8Q_IaYh4dmQx8POo0_xXEdtwxr0fjyH6FYdRN3jq-39W_Ta6j7Bu6f1BP24-vr94rqYzr7dXJxPCyMkzwW3DbNVCY1oeUvqloMsNeHSTmoj6qa2nMmm0WLCeVUJUlWkpbKUDalLY4kW_AR9ecxdDc0SWgM-j29Qq-iWOm5U0E79O_GuU4uwVkJIySkbAz4-BWz_BVJWS5cM9L32EIakaDkRggtR16P0w_OuvyV7GKOAPwpMDClFsMq4vAMzVrteUaK2yNUWuaJC7ZCPruI_1z74Zf0DyOOxnA
CitedBy_id crossref_primary_10_1007_s00347_019_00994_6
crossref_primary_10_1177_08853282211030150
crossref_primary_10_1177_0961203320979038
crossref_primary_10_1016_j_ophtha_2020_10_029
crossref_primary_10_1364_BOE_7_000581
crossref_primary_10_3390_diagnostics14161803
crossref_primary_10_1007_s00417_018_4117_3
crossref_primary_10_1371_journal_pone_0149138
crossref_primary_10_1097_IAE_0000000000002407
crossref_primary_10_1186_s12886_021_01977_5
crossref_primary_10_1016_j_ajo_2018_11_003
crossref_primary_10_1038_s41598_022_15217_3
crossref_primary_10_1080_1744666X_2023_2294938
crossref_primary_10_1097_IAE_0000000000002408
crossref_primary_10_1097_ICB_0000000000000421
crossref_primary_10_1016_j_lfs_2020_117963
crossref_primary_10_1038_s41433_020_01287_y
crossref_primary_10_1007_s00296_021_04831_5
crossref_primary_10_1016_j_ophtha_2022_05_002
crossref_primary_10_3389_fphar_2023_1196783
crossref_primary_10_1016_j_jfo_2017_08_002
crossref_primary_10_1007_s11655_024_3922_2
crossref_primary_10_1080_14656566_2024_2412252
crossref_primary_10_1136_bjophthalmol_2018_312363
crossref_primary_10_1007_s12035_022_02825_3
crossref_primary_10_1097_ICB_0000000000001388
crossref_primary_10_1007_s10792_020_01549_4
crossref_primary_10_1016_j_pdpdt_2022_102741
crossref_primary_10_3389_fmed_2022_1026934
crossref_primary_10_1097_ICB_0000000000001108
crossref_primary_10_1016_j_rcreu_2021_05_010
crossref_primary_10_3928_23258160_20160229_02
crossref_primary_10_1111_vop_12890
crossref_primary_10_1016_j_ophtha_2020_06_021
crossref_primary_10_1016_j_ophtha_2015_09_011
crossref_primary_10_15252_emmm_202012476
crossref_primary_10_1186_s12886_024_03684_3
crossref_primary_10_3390_biomedicines8030054
crossref_primary_10_1109_ACCESS_2018_2825397
crossref_primary_10_4103_IJO_IJO_740_23
crossref_primary_10_3390_jpm14050448
crossref_primary_10_1080_15569527_2024_2438629
crossref_primary_10_1097_IAE_0000000000001217
crossref_primary_10_1097_IAE_0000000000003638
crossref_primary_10_1038_eye_2016_298
crossref_primary_10_1016_j_prostaglandins_2020_106522
crossref_primary_10_3390_diagnostics13101752
crossref_primary_10_3390_jpm12091445
crossref_primary_10_1111_ceo_14090
crossref_primary_10_1167_iovs_64_12_29
crossref_primary_10_1364_BOE_9_002955
crossref_primary_10_1016_j_preteyeres_2021_100951
crossref_primary_10_1167_iovs_18_26079
crossref_primary_10_1080_02713683_2018_1545912
crossref_primary_10_1364_BOE_8_001926
crossref_primary_10_1177_0961203319829826
crossref_primary_10_1016_j_ajo_2022_07_028
crossref_primary_10_1097_IAE_0000000000001151
crossref_primary_10_1016_j_jcjo_2019_05_013
crossref_primary_10_1097_IAE_0000000000002047
crossref_primary_10_1097_IAE_0000000000001036
crossref_primary_10_1002_art_41934
crossref_primary_10_1016_j_ajoc_2018_01_019
crossref_primary_10_1167_tvst_12_3_5
crossref_primary_10_1097_IAE_0000000000002437
crossref_primary_10_18231_j_ijceo_2021_092
crossref_primary_10_1016_j_ajo_2017_08_022
crossref_primary_10_1097_ICB_0000000000000750
crossref_primary_10_1097_ICB_0000000000000993
crossref_primary_10_1167_tvst_12_7_8
crossref_primary_10_1016_j_ophtha_2016_04_042
crossref_primary_10_1016_j_oret_2019_04_025
crossref_primary_10_21561_jor_2024_9_1_62
crossref_primary_10_1097_MD_0000000000025688
crossref_primary_10_1016_j_ophtha_2016_01_058
crossref_primary_10_1016_j_media_2020_101893
crossref_primary_10_1159_000495308
crossref_primary_10_1167_tvst_9_9_42
ContentType Journal Article
Copyright Copyright 2015 The Association for Research in Vision and Ophthalmology, Inc. 2015
Copyright_xml – notice: Copyright 2015 The Association for Research in Vision and Ophthalmology, Inc. 2015
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1167/iovs.14-16345
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Retinal Layers in Progressive HCQ Retinopathy
EISSN 1552-5783
EndPage 3426
ExternalDocumentID PMC4455312
26024126
10_1167_iovs_14_16345
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NCATS NIH HHS
  grantid: UL1 TR001085
GroupedDBID ---
18M
2WC
34G
39C
5GY
5RE
AAYXX
ACGFO
ACNCT
ADBBV
AENEX
AFOSN
ALMA_UNASSIGNED_HOLDINGS
BAWUL
CITATION
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
GROUPED_DOAJ
GX1
N9A
OK1
P2P
RPM
SJN
TR2
TRV
W8F
WH7
WOQ
WOW
.55
.GJ
53G
AFFNX
AI.
CGR
CUY
CVF
ECM
EIF
NPM
VH1
X7M
ZGI
ZXP
7X8
5PM
ID FETCH-LOGICAL-c453t-3fb2f76eb4d3d09d3e56a035f89c49b9f325bba48337740770d1565b096cf0a43
ISSN 1552-5783
0146-0404
IngestDate Thu Aug 21 13:56:57 EDT 2025
Thu Jul 10 23:36:51 EDT 2025
Thu Apr 03 07:09:57 EDT 2025
Thu Apr 24 23:13:13 EDT 2025
Tue Jul 01 02:30:09 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c453t-3fb2f76eb4d3d09d3e56a035f89c49b9f325bba48337740770d1565b096cf0a43
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://iovs.arvojournals.org/arvo/content_public/journal/iovs/933929/i1552-5783-56-5-3415.pdf
PMID 26024126
PQID 1684434499
PQPubID 23479
PageCount 12
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4455312
proquest_miscellaneous_1684434499
pubmed_primary_26024126
crossref_citationtrail_10_1167_iovs_14_16345
crossref_primary_10_1167_iovs_14_16345
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2015-05-01
PublicationDateYYYYMMDD 2015-05-01
PublicationDate_xml – month: 05
  year: 2015
  text: 2015-05-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Investigative ophthalmology & visual science
PublicationTitleAlternate Invest Ophthalmol Vis Sci
PublicationYear 2015
Publisher The Association for Research in Vision and Ophthalmology
Publisher_xml – name: The Association for Research in Vision and Ophthalmology
References 21071737 - Invest Ophthalmol Vis Sci. 2011 Mar;52(3):1486-92
23661097 - Graefes Arch Clin Exp Ophthalmol. 2013 Oct;251(10):2311-7
23685488 - Indian J Ophthalmol. 2013 Apr;61(4):168-71
25301882 - Invest Ophthalmol Vis Sci. 2014 Nov;55(11):7093-103
25182842 - Ophthalmology. 2015 Jan;122(1):110-6
25425304 - Invest Ophthalmol Vis Sci. 2015 Jan;56(1):396-402
19373270 - Eye (Lond). 2010 Feb;24(2):340-6
102610 - Invest Ophthalmol Vis Sci. 1978 Dec;17(12):1158-75
21292109 - Ophthalmology. 2011 Feb;118(2):415-22
25275721 - JAMA Ophthalmol. 2014 Dec;132(12):1453-60
20395978 - Eye (Lond). 2010 May;24(5):756-62; quiz 763
22159170 - Arch Ophthalmol. 2012 Apr;130(4):461-9
24922444 - JAMA Ophthalmol. 2014 Sep;132(9):1105-12
22365056 - Ophthalmology. 2012 Jun;119(6):1151-8
References_xml – reference: 23685488 - Indian J Ophthalmol. 2013 Apr;61(4):168-71
– reference: 23661097 - Graefes Arch Clin Exp Ophthalmol. 2013 Oct;251(10):2311-7
– reference: 21292109 - Ophthalmology. 2011 Feb;118(2):415-22
– reference: 25301882 - Invest Ophthalmol Vis Sci. 2014 Nov;55(11):7093-103
– reference: 22159170 - Arch Ophthalmol. 2012 Apr;130(4):461-9
– reference: 22365056 - Ophthalmology. 2012 Jun;119(6):1151-8
– reference: 25182842 - Ophthalmology. 2015 Jan;122(1):110-6
– reference: 20395978 - Eye (Lond). 2010 May;24(5):756-62; quiz 763
– reference: 25425304 - Invest Ophthalmol Vis Sci. 2015 Jan;56(1):396-402
– reference: 25275721 - JAMA Ophthalmol. 2014 Dec;132(12):1453-60
– reference: 24922444 - JAMA Ophthalmol. 2014 Sep;132(9):1105-12
– reference: 21071737 - Invest Ophthalmol Vis Sci. 2011 Mar;52(3):1486-92
– reference: 19373270 - Eye (Lond). 2010 Feb;24(2):340-6
– reference: 102610 - Invest Ophthalmol Vis Sci. 1978 Dec;17(12):1158-75
SSID ssj0021120
Score 2.469582
Snippet To evaluate the relative involvement of inner and outer retina in hydroxychloroquine (HCQ) retinopathy while on the drug, and after drug cessation, using data...
This report examines the involvement of inner and outer retina in hydroxychloroquine (HCQ) retinopathy, using automated pixel-by-pixel segmentation to measure...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 3415
SubjectTerms Adult
Aged
Antimalarials - adverse effects
Antirheumatic Agents - adverse effects
Female
Fovea Centralis - pathology
Humans
Hydroxychloroquine - adverse effects
Male
Middle Aged
Retina
Retinal Diseases - chemically induced
Retinal Diseases - pathology
Tomography, Optical Coherence
Title Localization of Damage in Progressive Hydroxychloroquine Retinopathy On and Off the Drug: Inner Versus Outer Retina, Parafovea Versus Peripheral Fovea
URI https://www.ncbi.nlm.nih.gov/pubmed/26024126
https://www.proquest.com/docview/1684434499
https://pubmed.ncbi.nlm.nih.gov/PMC4455312
Volume 56
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bjtMwELXKIiFeEHfKTUZCvGRTkthxGt4QpepCl6JlV9q3yk4cNVKbrNqm0vIh_A6_xkycpOlukRZeqiqx07Rz6pnjzJwh5K1WiQ5E7Nuxo3wby2btkCfCDhOXBTwCXGsscD7-JkZn_Mu5f97p_G5lLRVr1Yt-7q0r-R-rwjGwK1bJ_oNlm4vCAXgP9oVXsDC83sjGY3REVSElRn0DucAUnDTD_P-SSGNe0OgyxlyVaAbUHNwAhpUnWOicYzfiS2ti0pEniUkWGCyLsgL6CHtyWbidVqysCTZ-MLOkiTuXMsk3WtYDvsPXLQUK5tYQj7dj3paUB9xNfjFbz-R8YbSfEHibdFXUpZlbnMXa-pGWKg5mIRsX6WqLwbq0u3EqJ4UyagimZt4a97Z77cuF2ZOoSgSsYa-91-H628zCenn2gToHpvVNvX4bYfIKp35rMQYH7e_3EgKfU6f5ZgWOwoaI1Cha7qpxX_GSTe5iyZpEMMXpQJym5fRb5LYHPAVbaAyOvjaM3zW6oM1t1yKvIni_8-m7QdE1pnM1YbcVAZ3eJ_cq6kI_Ghw-IB2dPSR3jqvkjEfkVxuONE-ogSNNM9qCI70OR9qCI51kFOBIAY4U4EgRjh9oCUZqsEZLMJo58pA2UKxPb6FISyg-JmfDz6efRnbV9sOOuM_WNkuUlwRCKx6z2Aljpn0hHeYn_TDioQoT5vlKSd5nDLiLEwRO7AItUUDGo8SRnD0hB1me6WeEKi9Qui-B1cB4z4v6DlMQwfJYxK7nxbJLDuvffRpVmvjYmmU-3WvlLnnXDL8wYjB_G_imNuIUlmt8BicznRcwQvQ5Z5yHYZc8NUZtLuUJCJhdT3RJsGPuZgBKwe-eydJZKQnPYZVlrvf8pjf4gtzd_r9ekoP1stCvILpeq9clgv8AOzLYsQ
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Localization+of+Damage+in+Progressive+Hydroxychloroquine+Retinopathy+On+and+Off+the+Drug%3A+Inner+Versus+Outer+Retina%2C+Parafovea+Versus+Peripheral+Fovea&rft.jtitle=Investigative+ophthalmology+%26+visual+science&rft.au=de+Sisternes%2C+Luis&rft.au=Hu%2C+Julia&rft.au=Rubin%2C+Daniel+L.&rft.au=Marmor%2C+Michael+F.&rft.date=2015-05-01&rft.issn=1552-5783&rft.volume=56&rft.issue=5&rft.spage=3415&rft_id=info:doi/10.1167%2Fiovs.14-16345&rft.externalDBID=n%2Fa&rft.externalDocID=10_1167_iovs_14_16345
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1552-5783&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1552-5783&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1552-5783&client=summon